3 years 4.8
Extreme 4.8
18.75
5 years 4.8
Extreme 4.8
52.43
10 years 4.8
Extreme 4.8
52.43
Manager TitleAgeSince
Chief Operating Officer - 28/08/2025
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 57 05/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/08/25 Tender

Chief Technology Officer

2,22,423 0.5811%
29/08/25 Tender

Chief Executive Officer; Director

11,06,638 2.8914%
29/08/25 Tender

Chief Operating Officer

5,78,671 1.5119%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%-.--% - - 45Cr
-6.60%-10.93%+45.08%+60.01% 6.9TCr
-4.09%-0.11%+2.31%+54.81% 5.31TCr
+0.03%+5.56%+10.18%+41.75% 5.08TCr
-2.29%+2.31%+29.22%+33.62% 4.46TCr
-6.06%-5.90%+259.42%+423.33% 4.06TCr
-1.36%+4.01%+15.93%+111.95% 4.25TCr
+6.53%+8.02%+18.98%+54.58% 3.09TCr
-0.90%-10.91%+34.11%-1.83% 2.54TCr
-2.62%-9.20%-16.22%-9.21% 2.27TCr
Average -1.73%+1.52%+44.34%+85.45% 4.22TCr
Weighted average by Cap. -2.54%+1.65%+45.67%+89.65%
Logo iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.
Employees
173
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITOS Stock